You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

 

1442 Results
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Funding:
ODB - General Benefit
    dexamethasone
Mar 2024
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Intent: Palliative
Funding:
New Drug Funding Program
    Glofitamab (Outpatient) - Relapsed or Refractory Diffuse Large B-cell Lymphoma
High Cost Therapy Funding Program
    Glofitamab (Inpatient) - Relapsed or Refractory Diffuse Large B-cell Lymphoma
Sep 2024
Regimen
Cancer Type:
Gastrointestinal, 
Hepatobiliary / Liver / Bile Duct
Intent: Palliative
Funding:
New Drug Funding Program
    Durvalumab - Locally Advanced Unresectable or Metastatic Biliary Tract Cancer
Regimen
Cancer Type:
Gastrointestinal, 
Hepatobiliary / Liver / Bile Duct
Intent: Palliative
Funding:
New Drug Funding Program
    Durvalumab - Locally Advanced Unresectable or Metastatic Biliary Tract Cancer
Regimen
Cancer Type:
Head and Neck, 
Nasopharynx
Intent: Palliative

Pages